{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T02:26:08Z","timestamp":1770690368019,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"S17","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["777123"],"award-info":[{"award-number":["777123"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In 2018, about 10 million people were found infected by tuberculosis, with approximately 1.2 million deaths worldwide. Despite these numbers have been relatively stable in recent years, tuberculosis is still considered one of the top 10 deadliest diseases worldwide. Over the years, Mycobacterium tuberculosis has developed a form of resistance to first-line tuberculosis treatments, specifically to isoniazid, leading to multi-drug-resistant tuberculosis. In this context, the EU and Indian DBT funded project STriTuVaD\u2014In Silico Trial for Tuberculosis Vaccine Development\u2014is supporting the identification of new interventional strategies against tuberculosis thanks to the use of Universal Immune System Simulator (UISS), a computational framework capable of predicting the immunity induced by specific drugs such as therapeutic vaccines and antibiotics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Here, we present how UISS accurately simulates tuberculosis dynamics and its interaction within the immune system, and how it predicts the efficacy of the combined action of isoniazid and RUTI vaccine in a specific digital population cohort. Specifically, we simulated two groups of 100 digital patients. The first group was treated with isoniazid only, while the second one was treated with the combination of RUTI vaccine and isoniazid, according to the dosage strategy described in the clinical trial design. UISS-TB shows to be in good agreement with clinical trial results suggesting that RUTI vaccine may favor a partial recover of infected lung tissue.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In silico trials innovations represent a powerful pipeline for the prediction of the effects of specific therapeutic strategies and related clinical outcomes. Here, we present a further step in UISS framework implementation. Specifically, we found that the simulated mechanism of action of RUTI and INH are in good alignment with the results coming from past clinical phase IIa trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-020-03762-5","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T01:02:38Z","timestamp":1607907758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Moving forward through the in silico modeling of tuberculosis: a further step with UISS-TB"],"prefix":"10.1186","volume":"21","author":[{"given":"Giulia","family":"Russo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Sgroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe Alessandro","family":"Parasiliti Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzio","family":"Pennisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere-Joan","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santo","family":"Motta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth B.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Epifanio","family":"Fichera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Viceconti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pappalardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"3762_CR1","unstructured":"WHO. Global tuberculosis report 2019. 2019."},{"key":"3762_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1055\/s-0038-1651492","volume":"39","author":"P Glaziou","year":"2018","unstructured":"Glaziou P, Floyd K, Raviglione MC. Global epidemiology of tuberculosis. Semin Respir Crit Care Med. 2018;39:271\u201385.","journal-title":"Semin Respir Crit Care Med"},{"key":"3762_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/med.21602","volume":"40","author":"A Bahuguna","year":"2020","unstructured":"Bahuguna A, Rawat DS. An overview of new antitubercular drugs, drug candidates, and their targets. Med Res Rev. 2020;40:263\u201392.","journal-title":"Med Res Rev"},{"key":"3762_CR4","doi-asserted-by":"publisher","unstructured":"Nath H, Ryoo S. First- and second-line drugs and drug resistance. In: Tuberculosis\u2014current issues in diagnosis and management. InTech; 2013. p. 13. https:\/\/doi.org\/10.5772\/54960.","DOI":"10.5772\/54960"},{"key":"3762_CR5","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/j.1365-2958.2006.05467.x","volume":"62","author":"GS Timmins","year":"2006","unstructured":"Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol Microbiol. 2006;62:1220\u20137.","journal-title":"Mol Microbiol"},{"key":"3762_CR6","first-page":"400","volume":"33","author":"HJM Meller","year":"1912","unstructured":"Meller HJM. Hydrazine derivatives of pyridinecarboxylic acids. Monatsschr Psychiatr. 1912;33:400.","journal-title":"Monatsschr Psychiatr"},{"key":"3762_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1586\/eri.12.91","volume":"10","author":"L Favrot","year":"2012","unstructured":"Favrot L, Ronning DR. Targeting the mycobacterial envelope for tuberculosis drug development. Expert Rev Anti Infect Ther. 2012;10:1023\u201336.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"3762_CR8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1208\/s12249-011-9654-6","volume":"12","author":"S Tiwari","year":"2011","unstructured":"Tiwari S, Chaturvedi AP, Tripathi YB, Mishra B. Macrophage-specific targeting of isoniazid through mannosylated gelatin microspheres. AAPS PharmSciTech. 2011;12:900\u20138.","journal-title":"AAPS PharmSciTech"},{"key":"3762_CR9","first-page":"765","volume":"65","author":"G Middlebrook","year":"1952","unstructured":"Middlebrook G. Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. Am Rev Tuberc. 1952;65:765\u20137.","journal-title":"Am Rev Tuberc"},{"issue":"2 Part 2","key":"3762_CR10","first-page":"109","volume":"74","author":"DA Mitchison","year":"1956","unstructured":"Mitchison DA, Selkon JB. The bactericidal activities of antituberculous drugs. Am Rev Tuberc. 1956;74(2 Part 2):109\u201316 (discussion 116\u201323).","journal-title":"Am Rev Tuberc."},{"key":"3762_CR11","first-page":"125","volume":"69","author":"WB Schaefer","year":"1954","unstructured":"Schaefer WB. The effect of isoniazid on growing and resting tubercle bacilli. Am Rev Tuberc. 1954;69:125\u20137.","journal-title":"Am Rev Tuberc"},{"key":"3762_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.meegid.2016.09.004","volume":"45","author":"AN Unissa","year":"2016","unstructured":"Unissa AN, Subbian S, Hanna LE, Selvakumar N. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect Genet Evol. 2016;45:474\u201392.","journal-title":"Infect Genet Evol"},{"key":"3762_CR13","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/s12859-019-3045-5","volume":"20","author":"M Pennisi","year":"2019","unstructured":"Pennisi M, Russo G, Sgroi G, Bonaccorso A, Parasiliti Palumbo GA, Fichera E, et al. Predicting the artificial immunity induced by RUTI\u00ae vaccine against tuberculosis using universal immune system simulator (UISS). BMC Bioinformatics. 2019;20:504. https:\/\/doi.org\/10.1186\/s12859-019-3045-5.","journal-title":"BMC Bioinformatics"},{"key":"3762_CR14","doi-asserted-by":"publisher","first-page":"e89612","DOI":"10.1371\/journal.pone.0089612","volume":"9","author":"AS Nell","year":"2014","unstructured":"Nell AS, D\u2019Lom E, Bouic P, Sabat\u00e9 M, Bosser R, Picas J, et al. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS ONE. 2014a;9:e89612.","journal-title":"PLoS ONE"},{"key":"3762_CR15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/cells9030586","volume":"9","author":"F Pappalardo","year":"2020","unstructured":"Pappalardo F, Russo G, Pennisi M, Parasiliti Palumbo GA, Sgroi G, Motta S, et al. The potential of computational modeling to predict disease course and treatment response in patients with relapsing multiple sclerosis. Cells. 2020;9:586. https:\/\/doi.org\/10.3390\/cells9030586.","journal-title":"Cells"},{"key":"3762_CR16","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1093\/bioinformatics\/btw293","volume":"32","author":"F Pappalardo","year":"2016","unstructured":"Pappalardo F, Fichera E, Paparone N, Lombardo A, Pennisi M, Russo G, et al. A computational model to predict the immune system activation by citrus-derived vaccine adjuvants. Bioinformatics. 2016;32:2672\u201380. https:\/\/doi.org\/10.1093\/bioinformatics\/btw293.","journal-title":"Bioinformatics"},{"key":"3762_CR17","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/bioinformatics\/bti426","volume":"21","author":"F Pappalardo","year":"2005","unstructured":"Pappalardo F, Lollini PL, Castiglione F, Motta S. Modeling and simulation of cancer immunoprevention vaccine. Bioinformatics. 2005;21:2891\u20137.","journal-title":"Bioinformatics"},{"key":"3762_CR18","doi-asserted-by":"crossref","unstructured":"Russo G, Pennisi M, Viceconti M, Pappalardo F. In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform. 2020.","DOI":"10.1101\/2020.05.06.080630"},{"issue":"Suppl 1","key":"3762_CR19","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1186\/1471-2105-14-S16-S9","volume":"14","author":"M Pennisi","year":"2013","unstructured":"Pennisi M, Rajput A-M, Toldo L, Pappalardo F. Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis. BMC Bioinformatics. 2013;14(Suppl 1):S9. https:\/\/doi.org\/10.1186\/1471-2105-14-S16-S9.","journal-title":"BMC Bioinformatics"},{"key":"3762_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s12859-017-1961-9","volume":"18","author":"M Pennisi","year":"2017","unstructured":"Pennisi M, Russo G, Ravalli S, Pappalardo F. Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus. BMC Bioinformatics. 2017;18:544. https:\/\/doi.org\/10.1186\/s12859-017-1961-9.","journal-title":"BMC Bioinformatics"},{"key":"3762_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1140\/epjp\/i2015-15159-4","volume":"130","author":"C Bianca","year":"2015","unstructured":"Bianca C, Riposo J. Mimic therapeutic actions against keloid by thermostatted kinetic theory methods. Eur Phys J Plus. 2015;130:159.","journal-title":"Eur Phys J Plus."},{"key":"3762_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.camwa.2010.11.003","volume":"61","author":"C Bianca","year":"2011","unstructured":"Bianca C, Fermo L. Bifurcation diagrams for the moments of a kinetic type model of keloid\u2013immune system competition. Comput Math with Appl. 2011;61:277\u201388.","journal-title":"Comput Math with Appl."},{"key":"3762_CR23","doi-asserted-by":"publisher","unstructured":"Pennisi M, Juarez MA, Russo G, Viceconti M, Pappalardo F. Generation of digital patients for the simulation of tuberculosis with UISS-TB. In: 2019 IEEE international conference on bioinformatics and biomedicine (BIBM). San Diego, CA, USA, USA: IEEE; 2019. pp. 2163\u20137. doi:https:\/\/doi.org\/10.1109\/BIBM47256.2019.8983100.","DOI":"10.1109\/BIBM47256.2019.8983100"},{"key":"3762_CR24","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1128\/AAC.03728-14","volume":"58","author":"G Russo","year":"2019","unstructured":"Russo G, Pappalardo F, Juarez MA, Pennisi M, Cardona PJ, Coler R, et al. Evaluation of the efficacy of RUTI and ID93\/GLA-SE vaccines in tuberculosis treatment: in silico trial through UISS-TB simulator. Antimicrob Agents Chemother. 2019;58:7250\u20137. https:\/\/doi.org\/10.1128\/AAC.03728-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"3762_CR25","unstructured":"Abbas Abul K., Lichtman; AH, Pillai S. Cellular and molecular immunology. 2014."},{"key":"3762_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/cmi.2017.128","volume":"15","author":"H Shen","year":"2018","unstructured":"Shen H, Chen ZW. The crucial roles of Th17-related cytokines\/signal pathways in M. tuberculosis infection. Cell Mol Immunol. 2018;15:216\u201325.","journal-title":"Cell Mol Immunol."},{"key":"3762_CR27","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1002\/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4","volume":"30","author":"LA van Pinxteren","year":"2000","unstructured":"van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol. 2000;30:3689\u201398.","journal-title":"Eur J Immunol"},{"key":"3762_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0089612","volume":"9","author":"AS Nell","year":"2014","unstructured":"Nell AS, D\u2019Lom E, Bouic P, Sabat\u00e9 M, Bosser R, Picas J, et al. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS ONE. 2014b;9:1\u201310.","journal-title":"PLoS ONE"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-020-03762-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12859-020-03762-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-020-03762-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T01:02:55Z","timestamp":1607907775000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-020-03762-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":28,"journal-issue":{"issue":"S17","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3762"],"URL":"https:\/\/doi.org\/10.1186\/s12859-020-03762-5","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"14 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"458"}}